治療薬モニタリング市場：製品、技術、薬剤クラス別、エンドユーザー別-2025-2030年の世界予測

治療薬モニタリング市場は、2023年に37億9,000万米ドルと評価され、2024年には43億8,000万米ドルに達すると予測され、CAGR 16.11％で成長し、2030年には107億8,000万米ドルに達すると予測されています。

治療薬モニタリング（TDM）には、毒性を最小限に抑えながら投与量を最適化し、治療効果を最大化するために、血流中の薬物濃度を測定することが含まれます。TDMの必要性は、薬物の吸収、分布、代謝、排泄における患者のばらつきにより、投薬レジメンを個別化する必要性から生じる。TDMの用途には、主に抗けいれん薬、抗生物質、免疫抑制剤など治療域の狭い薬剤が含まれ、副作用を抑えながら効果的な治療を保証する個別化医療において極めて重要です。最終用途の範囲は主に病院、研究所、臨床現場［薬物動態ユニット］に及び、治療の有効性と安全性の向上に積極的に取り組んでいます。TDMの市場成長は、慢性疾患の有病率の上昇、薬理ゲノミクスの進歩、個別化医療への注目の高まりなどの要因に影響されるが、検査費用の高騰、厳しい規制の枠組み、熟練した専門家の必要性などの課題が成長の妨げになる可能性があります。さらに、TDMは、ポイントオブケア検査の革新と予測モニタリングのためのAIの統合により、リアルタイムの薬物モニタリングと患者の転帰改善の道を開く潜在的な機会を提供します。こうした機会を活用するために、利害関係者は費用対効果の高いTDMソリューションを創出するための研究開発に投資し、バイオテクノロジー企業やヘルスケア施設との戦略的パートナーシップを育み、参入範囲と適応性を拡大すべきです。市場の限界には、技術的限界や未開発地域における認識不足などがあるが、非侵襲的サンプリングや迅速診断技術の進歩により、これらの課題を大幅に克服できる可能性があります。技術革新の最も有望な分野には、携帯可能で使い勝手の良いモニタリング機器の開発や、より正確で実用的な知見を提供するためのデータ分析機能の強化が含まれます。全体として、技術革新、手頃な価格、患者中心のソリューションに戦略的に焦点を当てることが、市場の持続的成長とダイナミックな治療薬モニタリング分野における新たな機会の獲得に最も重要であろう。

市場力学：急速に進化する治療薬モニタリング市場の主要市場インサイトを公開

治療薬モニタリング市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的意思決定、新たなビジネスチャンスの獲得を行うことができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができるとともに、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 個別化医療に対する需要の高まり
  • 様々な治療分野における治療薬モニタリングの採用増加
  • 固形臓器移植患者における使用と重要性の高まり
• 市場抑制要因
  • 不十分な償還政策
  • 高額な設備投資の必要性
• 市場機会
  • 発展途上国における治療薬モニタリングの将来展望
  • 免疫測定法およびその他の治療薬モニタリング技術の発展
• 市場の課題
  • 臨床課題と熟練検査技師の不足

ポーターのファイブフォース：治療薬モニタリング市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、治療薬モニタリング市場の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：治療薬モニタリング市場における外部からの影響の把握

外部マクロ環境要因は、治療薬モニタリング市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析治療薬モニタリング市場における競合情勢の把握

治療薬モニタリング市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス治療薬モニタリング市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、治療薬モニタリング市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限はベンダーを明確かつ正確に区分し、ユーザーが戦略目標に最適なパートナーやソリューションを特定するのに役立ちます。

本レポートは、主要な注目分野を網羅した包括的な市場分析を提供しています：

1.市場の浸透度：業界主要企業の広範なデータを含む、現在の市場環境の詳細なレビュー。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 個別化医療の需要増加
    • さまざまな治療分野で治療薬モニタリングの採用が増加
    • 固形臓器移植患者における使用と重要性の高まり
  • 抑制要因
    • 不十分な払い戻しポリシー
    • 多額の資本投資の必要性
  • 機会
    • 発展途上国における治療薬モニタリングの将来展望
    • 免疫測定法およびその他の治療薬モニタリング技術の発展
  • 課題
    • 臨床上の課題と熟練した検査技師の不足
• 市場セグメンテーション分析
  • 製品：効率的な医薬品管理のためのデータ管理サービスの需要の高まり
  • エンドユーザー：正確な薬剤管理が不可欠な病院からの需要増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境
• 顧客のカスタマイズ

第6章 治療薬モニタリング市場：製品別

• 消耗品
• データ管理サービス
• 装置
  • クロマトグラフィーおよび質量分析検出器
  • 臨床化学分析装置
  • 免疫測定分析装置

第7章 治療薬モニタリング市場：技術別

• クロマトグラフィー-MS
  • GC-MS
  • LC-MS
• 免疫測定
  • 化学発光免疫測定
  • 比色免疫測定法
  • 蛍光免疫測定
  • 放射免疫測定
• プロテオーム技術

第8章 治療薬モニタリング市場薬剤クラス別

• 抗不整脈薬
• 抗生物質
• 抗てんかん薬
• 気管支拡張薬
• 免疫抑制薬
• 向精神薬

第9章 治療薬モニタリング市場：エンドユーザー別

• 病院の検査室
• プライベートラボ

第10章 南北アメリカの治療薬モニタリング市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第11章 アジア太平洋地域の治療薬モニタリング市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第12章 欧州・中東・アフリカの治療薬モニタリング市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第13章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • CapitainerがAstraZenecaとの提携を発表。
  • Novo Holdingsがプロテオミクス技術企業Evosepに投資。
  • AegirBio ABは、TDMや唾液サンプル採取などへの投資を強化するために、ワラント付 5,500万スウェーデンクローナの転換社債に関してAtlas Special Opportunities, LLCと契約を締結しました。
  • 治療薬モニタリング分析のための臨床LC-MS法。
  • Boditech Medは4つのTDM製品の輸出ライセンスを取得しました。
  • Pace社、GC-MS/MS技術によるダイオキシンおよびジベンゾフランの検出方法についてEPAの承認を取得。
  • Bio-Rad社、バイオ分析および薬物モニタリング用の抗イディオタイプ抗体のラインアップを拡大。
  • Beckman Coulter社とSaladax Biomedical社が抗精神病薬治療薬モニタリングで提携。
  • Ampersand Capital Partnersが、大手SIFT-MSソリューションプロバイダーであるSyft Technologiesに投資しました。

企業一覧

• apDia Group
• Cambridge Life Sciences Limited
• Danaher Corporation
• ARK Diagnostics, Inc.
• Assay Genie
• DiaSorin SpA
• Merck KGaA
• Grifols, S.A.
• Siemens Healthineers AG
• Cardinal Health, Inc.
• Pfizer Inc.
• DiaSystem Scandinavia AB
• R-Biopharm AG
• Bio-Rad Laboratories, Inc.
• Krishgen Biosystems
• H.U. Group Holdings, Inc.
• Buhlmann Laboratories AG
• Myriad Genetics, Inc.
• Theradiag SA
• Randox Laboratories, Ltd.
• Thermo Fisher Scientific, Inc.
• Tecan Trading AG
• OneCare Media, LLC
• Chromsystems Instruments & Chemicals GmbH
• Agilent Technologies, Inc.
• Eagle Biosciences, Inc.
• Svar Life Science AB
• Sekisui Chemical Co Ltd.
• Neoteryx, LLC by Trajan Group
• Veolia Group
• bioMerieux SA
• ARUP Laboratories
• Abbott Laboratories
• F. Hoffmann-La Roche AG
• Exagen Inc.

LIST OF FIGURES

• FIGURE 1. THERAPEUTIC DRUG MONITORING MARKET RESEARCH PROCESS
• FIGURE 2. THERAPEUTIC DRUG MONITORING MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
• FIGURE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 15. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 17. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 21. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 22. THERAPEUTIC DRUG MONITORING MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 23. THERAPEUTIC DRUG MONITORING MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. THERAPEUTIC DRUG MONITORING MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. THERAPEUTIC DRUG MONITORING MARKET DYNAMICS
• TABLE 7. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CONSUMABLES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DATA MANAGEMENT SERVICES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY & MS DETECTORS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CLINICAL CHEMISTRY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAY ANALYZERS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY GC-MS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY LC-MS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHEMILUMINESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COLORIMETRIC IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY FLUORESCENCE IMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY RADIOIMMUNOASSAYS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PROTEOMIC TECHNOLOGIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 28. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIARRHYTHMIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 29. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIBIOTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 30. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY ANTIEPILEPTIC DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 31. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY BRONCHODILATOR DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 32. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOSUPPRESSANT DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 33. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PSYCHOACTIVE DRUGS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 34. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 35. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY HOSPITAL LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 36. GLOBAL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRIVATE LABS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 37. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 38. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 39. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 40. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 41. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 42. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 43. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 44. AMERICAS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 45. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 46. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 47. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 48. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 49. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 50. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 51. ARGENTINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 52. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 53. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 54. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 55. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 56. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 57. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 58. BRAZIL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 59. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 60. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 61. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 62. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 63. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 64. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 65. CANADA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 66. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 67. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 68. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 69. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 70. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 71. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 72. MEXICO THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 73. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 74. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 75. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 76. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 77. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 78. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 79. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 80. UNITED STATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 81. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 82. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 83. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 84. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 85. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 86. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 87. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 88. ASIA-PACIFIC THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 89. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 90. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 91. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 92. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 93. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 94. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 95. AUSTRALIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 96. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 97. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 98. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 99. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 100. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 101. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 102. CHINA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 103. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 104. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 105. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 106. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 107. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 108. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 109. INDIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 110. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 111. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 112. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 113. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 114. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 115. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 116. INDONESIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 117. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 118. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 119. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 120. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 121. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 122. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 123. JAPAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 124. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 125. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 126. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 127. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 128. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 129. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 130. MALAYSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 131. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 132. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 133. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 134. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 135. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 136. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 137. PHILIPPINES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 138. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 139. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 140. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 141. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 142. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 143. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 144. SINGAPORE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 145. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 146. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 147. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 148. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 149. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 150. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 151. SOUTH KOREA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 152. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 153. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 154. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 155. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 156. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 157. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 158. TAIWAN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 159. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 160. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 161. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 162. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 163. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 164. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 165. THAILAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 166. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 167. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 168. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 169. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 170. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 171. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 172. VIETNAM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 173. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 174. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 175. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 176. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 177. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 178. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 179. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 180. EUROPE, MIDDLE EAST & AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 181. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 182. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 183. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 184. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 185. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 186. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 187. DENMARK THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 188. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 189. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 190. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 191. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 192. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 193. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 194. EGYPT THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 195. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 196. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 197. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 198. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 199. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 200. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 201. FINLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 202. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 203. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 204. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 205. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 206. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 207. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 208. FRANCE THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 209. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 210. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 211. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 212. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 213. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 214. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 215. GERMANY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 216. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 217. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 218. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 219. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 220. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 221. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 222. ISRAEL THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 223. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 224. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 225. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 226. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 227. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 228. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 229. ITALY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 230. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 231. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 232. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 233. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 234. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 235. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 236. NETHERLANDS THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 237. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 238. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 239. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 240. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 241. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 242. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 243. NIGERIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 244. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 245. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 246. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 247. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 248. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 249. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 250. NORWAY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 251. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 252. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 253. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 254. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 255. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 256. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 257. POLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 258. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 259. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 260. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 261. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 262. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 263. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 264. QATAR THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 265. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 266. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 267. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 268. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 269. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 270. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 271. RUSSIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 272. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 273. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 274. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 275. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 276. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 277. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 278. SAUDI ARABIA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 279. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 280. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 281. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 282. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 283. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 284. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 285. SOUTH AFRICA THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 286. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 287. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 288. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 289. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 290. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 291. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 292. SPAIN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 293. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 294. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 295. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 296. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 297. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 298. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 299. SWEDEN THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 300. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 301. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 302. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 303. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 304. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 305. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 306. SWITZERLAND THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 307. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 308. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 309. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 310. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 311. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 312. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 313. TURKEY THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 314. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 315. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 316. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 317. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY CHROMATOGRAPHY-MS, 2018-2030 (USD MILLION)
• TABLE 318. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY IMMUNOASSAYS, 2018-2030 (USD MILLION)
• TABLE 319. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
• TABLE 320. UNITED ARAB EMIRATES THERAPEUTIC DRUG MONITORING MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
• TABLE 321. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
• TABLE 322. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY EQUIPMENT, 2018-2030 (USD MILLION)
• TABLE 323. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
• TABLE 324. UNITED KINGDOM THERAPEUTIC DRUG MONITORING MARKET SIZ

The Therapeutic Drug Monitoring Market was valued at USD 3.79 billion in 2023, expected to reach USD 4.38 billion in 2024, and is projected to grow at a CAGR of 16.11%, to USD 10.78 billion by 2030.

Therapeutic Drug Monitoring (TDM) involves measuring drug concentrations in the bloodstream to optimize dosage and maximize therapeutic efficacy while minimizing toxicity. The necessity of TDM arises from the need to individualize medication regimens due to patient variability in drug absorption, distribution, metabolism, and excretion. Applications of TDM primarily include drugs with narrow therapeutic ranges, such as anticonvulsants, antibiotics, and immunosuppressants, and are crucial in personalized medicine, ensuring effective treatment while reducing adverse effects. The end-use scope primarily extends to hospitals, laboratories, and clinical settings [pharmacokinetic units], actively engaged in increasing treatment efficacy and safety. The market growth of TDM is influenced by factors such as the rising prevalence of chronic diseases, advancements in pharmacogenomics, and an increased focus on personalized medicine; however, challenges such as the high cost of testing, strict regulatory frameworks, and the need for skilled professionals could hamper growth. Moreover, TDM presents potential opportunities with innovations in point-of-care testing and the integration of AI for predictive monitoring, creating avenues for real-time drug monitoring and improving patient outcomes. To leverage these opportunities, stakeholders should invest in research and development to create cost-effective TDM solutions, fostering strategic partnerships with biotech firms and healthcare facilities to broaden their reach and adaptability. While market limitations include technological limitations and a lack of awareness in undeveloped regions, advancements in non-invasive sampling and rapid diagnostic techniques could significantly surmount these challenges. The most promising areas for innovation encompass developing portable and user-friendly monitoring devices and enhancing data analytics capabilities to deliver more precise and actionable insights. Overall, a strategic focus on innovation, affordability, and patient-centric solutions would be paramount for sustained market growth and capturing emerging opportunities in the dynamic field of Therapeutic Drug Monitoring.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Therapeutic Drug Monitoring Market

The Therapeutic Drug Monitoring Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Increased Demand for Personalized Medicine
  • Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
  • Growing Use and Importance in Patients with Solid Organ Transplantation
• Market Restraints
  • Inadequate Reimbursement Policies
  • Need of High Capital Investments
• Market Opportunities
  • Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
  • Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
• Market Challenges
  • Clinical Challenges and Limited Availability of Skilled Laboratory Technicians

Porter's Five Forces: A Strategic Tool for Navigating the Therapeutic Drug Monitoring Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Therapeutic Drug Monitoring Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Therapeutic Drug Monitoring Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Therapeutic Drug Monitoring Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Therapeutic Drug Monitoring Market

A detailed market share analysis in the Therapeutic Drug Monitoring Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Therapeutic Drug Monitoring Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Therapeutic Drug Monitoring Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Therapeutic Drug Monitoring Market, highlighting leading vendors and their innovative profiles. These include apDia Group, Cambridge Life Sciences Limited, Danaher Corporation, ARK Diagnostics, Inc., Assay Genie, DiaSorin SpA, Merck KGaA, Grifols, S.A., Siemens Healthineers AG, Cardinal Health, Inc., Pfizer Inc., DiaSystem Scandinavia AB, R-Biopharm AG, Bio-Rad Laboratories, Inc., Krishgen Biosystems, H.U. Group Holdings, Inc., Buhlmann Laboratories AG, Myriad Genetics, Inc., Theradiag SA, Randox Laboratories, Ltd., Thermo Fisher Scientific, Inc., Tecan Trading AG, OneCare Media, LLC, Chromsystems Instruments & Chemicals GmbH, Agilent Technologies, Inc., Eagle Biosciences, Inc., Svar Life Science AB, Sekisui Chemical Co Ltd., Neoteryx, LLC by Trajan Group, Veolia Group, bioMerieux SA, ARUP Laboratories, Abbott Laboratories, F. Hoffmann-La Roche AG, and Exagen Inc..

Market Segmentation & Coverage

This research report categorizes the Therapeutic Drug Monitoring Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Product, market is studied across Consumables, Data Management Services, and Equipment. The Equipment is further studied across Chromatography & MS Detectors, Clinical Chemistry Analyzers, and Immunoassay Analyzers.
• Based on Technology, market is studied across Chromatography-MS, Immunoassays, and Proteomic Technologies. The Chromatography-MS is further studied across GC-MS and LC-MS. The Immunoassays is further studied across Chemiluminescence Immunoassays, Colorimetric Immunoassays, Fluorescence Immunoassays, and Radioimmunoassays.
• Based on Drug Class, market is studied across Antiarrhythmic Drugs, Antibiotic Drugs, Antiepileptic Drugs, Bronchodilator Drugs, Immunosuppressant Drugs, and Psychoactive Drugs.
• Based on End-User, market is studied across Hospital Labs and Private Labs.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Increased Demand for Personalized Medicine
    • 5.1.1.2. Rising Adoption of Therapeutic Drug Monitoring Across Various Therapeutic Fields
    • 5.1.1.3. Growing Use and Importance in Patients with Solid Organ Transplantation
  • 5.1.2. Restraints
    • 5.1.2.1. Inadequate Reimbursement Policies
    • 5.1.2.2. Need of High Capital Investments
  • 5.1.3. Opportunities
    • 5.1.3.1. Future Perspectives of Therapeutic Drug Monitoring in Developing Nations
    • 5.1.3.2. Developments in Immunoassay and Other Therapeutic Drug Monitoring Technologies
  • 5.1.4. Challenges
    • 5.1.4.1. Clinical Challenges and Limited Availability of Skilled Laboratory Technicians
• 5.2. Market Segmentation Analysis
  • 5.2.1. Product: Rising demand for data management services for efficient drug management
  • 5.2.2. End-User: Increasing demand from hospitals where accurate drug management is essential
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental
• 5.5. Client Customization

6. Therapeutic Drug Monitoring Market, by Product

• 6.1. Introduction
• 6.2. Consumables
• 6.3. Data Management Services
• 6.4. Equipment
  • 6.4.1. Chromatography & MS Detectors
  • 6.4.2. Clinical Chemistry Analyzers
  • 6.4.3. Immunoassay Analyzers

7. Therapeutic Drug Monitoring Market, by Technology

• 7.1. Introduction
• 7.2. Chromatography-MS
  • 7.2.1. GC-MS
  • 7.2.2. LC-MS
• 7.3. Immunoassays
  • 7.3.1. Chemiluminescence Immunoassays
  • 7.3.2. Colorimetric Immunoassays
  • 7.3.3. Fluorescence Immunoassays
  • 7.3.4. Radioimmunoassays
• 7.4. Proteomic Technologies

8. Therapeutic Drug Monitoring Market, by Drug Class

• 8.1. Introduction
• 8.2. Antiarrhythmic Drugs
• 8.3. Antibiotic Drugs
• 8.4. Antiepileptic Drugs
• 8.5. Bronchodilator Drugs
• 8.6. Immunosuppressant Drugs
• 8.7. Psychoactive Drugs

9. Therapeutic Drug Monitoring Market, by End-User

• 9.1. Introduction
• 9.2. Hospital Labs
• 9.3. Private Labs

10. Americas Therapeutic Drug Monitoring Market

• 10.1. Introduction
• 10.2. Argentina
• 10.3. Brazil
• 10.4. Canada
• 10.5. Mexico
• 10.6. United States

11. Asia-Pacific Therapeutic Drug Monitoring Market

• 11.1. Introduction
• 11.2. Australia
• 11.3. China
• 11.4. India
• 11.5. Indonesia
• 11.6. Japan
• 11.7. Malaysia
• 11.8. Philippines
• 11.9. Singapore
• 11.10. South Korea
• 11.11. Taiwan
• 11.12. Thailand
• 11.13. Vietnam

12. Europe, Middle East & Africa Therapeutic Drug Monitoring Market

• 12.1. Introduction
• 12.2. Denmark
• 12.3. Egypt
• 12.4. Finland
• 12.5. France
• 12.6. Germany
• 12.7. Israel
• 12.8. Italy
• 12.9. Netherlands
• 12.10. Nigeria
• 12.11. Norway
• 12.12. Poland
• 12.13. Qatar
• 12.14. Russia
• 12.15. Saudi Arabia
• 12.16. South Africa
• 12.17. Spain
• 12.18. Sweden
• 12.19. Switzerland
• 12.20. Turkey
• 12.21. United Arab Emirates
• 12.22. United Kingdom

13. Competitive Landscape

• 13.1. Market Share Analysis, 2023
• 13.2. FPNV Positioning Matrix, 2023
• 13.3. Competitive Scenario Analysis
  • 13.3.1. Capitainer announces collaboration with AstraZeneca.
  • 13.3.2. Novo Holdings invests in proteomics technology company, Evosep.
  • 13.3.3. AegirBio AB enters into an agreement with Atlas Special Opportunities, LLC regarding convertible bonds of SEK 55 million with attached warrants to intensify investments in i.a. TDM and saliva sampling.
  • 13.3.4. Clinical LC-MS methods for therapeutic drug monitoring analysis.
  • 13.3.5. Boditech Med has obtained the export license of four TDM products.
  • 13.3.6. Pace Obtains EPA Approval on Method for Detecting Dioxins and Dibenzofurans Through GC-MS/MS Technology.
  • 13.3.7. Bio-Rad Extends Range of Anti-Idiotypic Antibodies for Bioanalysis and Drug Monitoring.
  • 13.3.8. Beckman Coulter and Saladax Biomedical Team Up on Antipsychotic Therapeutic Drug Monitoring.
  • 13.3.9. Ampersand Capital Partners Invests in Syft Technologies, Leading SIFT-MS Solutions Provider.

Companies Mentioned

• 1. apDia Group
• 2. Cambridge Life Sciences Limited
• 3. Danaher Corporation
• 4. ARK Diagnostics, Inc.
• 5. Assay Genie
• 6. DiaSorin SpA
• 7. Merck KGaA
• 8. Grifols, S.A.
• 9. Siemens Healthineers AG
• 10. Cardinal Health, Inc.
• 11. Pfizer Inc.
• 12. DiaSystem Scandinavia AB
• 13. R-Biopharm AG
• 14. Bio-Rad Laboratories, Inc.
• 15. Krishgen Biosystems
• 16. H.U. Group Holdings, Inc.
• 17. Buhlmann Laboratories AG
• 18. Myriad Genetics, Inc.
• 19. Theradiag SA
• 20. Randox Laboratories, Ltd.
• 21. Thermo Fisher Scientific, Inc.
• 22. Tecan Trading AG
• 23. OneCare Media, LLC
• 24. Chromsystems Instruments & Chemicals GmbH
• 25. Agilent Technologies, Inc.
• 26. Eagle Biosciences, Inc.
• 27. Svar Life Science AB
• 28. Sekisui Chemical Co Ltd.
• 29. Neoteryx, LLC by Trajan Group
• 30. Veolia Group
• 31. bioMerieux SA
• 32. ARUP Laboratories
• 33. Abbott Laboratories
• 34. F. Hoffmann-La Roche AG
• 35. Exagen Inc.